Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Colorado
Clinical trial register · United States · industry-sponsored

Clinical Trials in Colorado, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 5290 Florida 4430 Illinois 2481 Georgia 2368 Arizona 2238
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca87 Janssen Research & Development, LLC71 Eli Lilly and Company65 Merck Sharp & Dohme LLC64 Novartis Pharmaceuticals56
State
California5290 Florida4430 Illinois2481 Georgia2368 Arizona2238
All 51 states
Target enrolment
to

Trials with a site in Colorado

2068 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Missouri
2027-11-23
Not yet open
Clinical Outcomes of Focused Shockwave Therapy Without Adjunct Rehabilitation Compared to Standard Physical Rehabilitation in Patients With Grade I-III Knee Osteoarthritis: A Single-Blind Randomized Study
NCT07567365Knee Osteoarthristis
Pulse Wave USA
Not applicable
60
Colorado
2027-09-25
Not yet open
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562Systemic Sclerosis
DrugsZola-cel·Nintedanib·Tocilizumab·Fludarabine
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Arizona, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2027-02-03
Not yet open
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
NCT07815574Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
DrugsImmunoBody·Yervoy·Ipilimumab·Opdivo
Scancell Ltd
Phase 3
550
Colorado
2026-12-01
Not yet open
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
NCT07728188Relapsed or Refractory Multiple Myeloma
DrugsEtentamig·Teclistamab·Carfilzomib·Pomalidomide
AbbVie
Phase 3
520
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts
2026-11-30
Not yet open
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015Idiopathic Inflammatory Myopathies
DrugNerandomilast
Boehringer Ingelheim
Phase 3
270
Arizona, California, Colorado, Florida, Kansas, Maryland, Massachusetts, Michigan
2026-11-09
Not yet open
Sacrum Pressure Injury Prevention Study Using ALLEVYN◊ Complete Care in Adults at Risk of Developing Hospital-acquired Pressure Injuries in Critical Care Units
NCT07849387Pressure Ulcers (Hospital-acquired Pressure Injuries)
Smith & Nephew, Inc.
Not applicable
330
Colorado, Georgia, Indiana
2026-10-30
Recruiting
Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure
NCT07775495Healthy Adult Participants
Ecotera Health LLC
Observational
15
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2026-10-21
Recruiting
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
NCT05909761Neuromyelitis Optica Spectrum Disorder, Pregnancy Related
DrugUplizna
Amgen
Observational
60
Colorado
2026-10-15
Recruiting
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
NCT07673744Myasthenia Gravis
DrugUblituximab
TG Therapeutics, Inc.
Phase 2
120
Colorado, Florida, Michigan, North Carolina, South Carolina
2026-10-01
Not yet open
A Study Examining Acceptability of Auditory Implant Fitting Software Technologies
NCT07763873Hearing Impairment
Cochlear
Not applicable
200
Colorado
2026-10
Recruiting
To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome
NCT06840496Rett Syndrome
Biomed Industries, Inc.
Phase 3
210
Arizona, California, Colorado, Florida, Illinois, Maryland, Massachusetts, New York
2026-09-30
Not yet open
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790Non-Small Cell Lung Cancer
DrugsIza-bren·Osimertinib·Pemetrexed·Cisplatin
Bristol-Myers Squibb
Phase 3
850
California, Colorado, Florida, Hawaii, Illinois, Maryland, Minnesota, Missouri
2026-09-30
Not yet open
Knee Cartilage Repair Registry
NCT07786207Knee Injuries, Joint Surface Knee Lesions
Smith & Nephew, Inc.
Observational
1,000
Colorado, District of Columbia, Indiana, Kentucky, Oklahoma, Pennsylvania
2026-09-30
Recruiting
A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury
NCT07799532Chronic Spinal Cord Injury
NervGen Pharma
Phase 3
150
Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Maryland
2026-09-28
Recruiting
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
NCT07700979Gastric / Gastroesophageal Junction Adenocarcinoma
DrugsFolfox·Cadonilimab·Nivolumab
Akeso
Phase 3
900
Arizona, California, Colorado, Connecticut, Massachusetts, Michigan, New York, Oregon
2026-09-24
Recruiting
An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin
NCT07845071Pain
Adneuris Therapeutics, Inc.
Phase 3
160
Arizona, California, Colorado, Georgia, Illinois, Maryland, New Jersey, Oklahoma
2026-09-22
Not yet open
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
NCT07768189Oropharyngeal Carcinoma (OPC)
DrugsCRB-701·Cetuximab·Docetaxel
Corbus Pharmaceuticals Inc.
Phase 3
260
Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa, Maryland
2026-09-20
Recruiting
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
NCT07701941Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
DrugsPatritumab deruxtecan·Trastuzumab deruxtecan
Daiichi Sankyo
Phase 1/2
220
California, Colorado, Connecticut, Massachusetts, New York, Oregon, Tennessee, Texas
2026-09-17
Recruiting
Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)
NCT07587021Primary Hyperoxaluria Type 1, PH1
YolTech Therapeutics Co., Ltd
Phase 2
36
Alabama, Colorado, Missouri, Pennsylvania
2026-09-16
Recruiting
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
NCT07412704Arthritis, Rheumatoid
Bristol-Myers Squibb
Phase 1/2
84
California, Colorado, Florida, New York, Oregon, Pennsylvania, Texas
2026-09-15
Recruiting
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
NCT07648264Secondary Immune Deficiency
DrugHizentra
CSL Behring
Phase 3
63
California, Colorado, Florida, Indiana, Maryland, New Jersey, New York, North Carolina
2026-09-15
Not yet open
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
NCT07284745Irritability Associated With Autism Spectrum Disorder
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2026-09-11
Recruiting
A Study in Adults With Geographic Atrophy
NCT07606365Geographic Atrophy
DrugSTL303
Sitala Bio LTD
Phase 2
300
California, Colorado, Connecticut, Illinois, Maryland, Massachusetts, New York, Pennsylvania
2026-09-11
Recruiting
Device for Treating Generalized Anxiety
NCT07819773Generalized Anxiety Disorder (GAD)
BTL Industries Ltd.
Not applicable
40
Colorado, Illinois, Indiana
2026-09-09
Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200Essential Thrombocythemia
DrugINCA033989
Incyte Corporation
Phase 3
426
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas
2026-09-08
Recruiting
Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
NCT07465718Wilson's Disease
Orphalan
Phase 3
38
Colorado, Connecticut, Michigan
2026-09-03
Recruiting
A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age
NCT07805707Influenza, Human
GlaxoSmithKline
Phase 3
54,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-09-02
Not yet open
To Evaluate the Clinical Impact of the Point Powered System
NCT07135947Amputation; Traumatic, Hand
Point Designs
Not applicable
10
Colorado
2026-09-01
Not yet open
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07816367Migraine
DrugElismetrep
Kallyope Inc.
Phase 3
1,500
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2026-09
Recruiting
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
NCT07594119Focal Seizure, Epilepsy, Focal Epilepsy
DrugRAP-219
Rapport Therapeutics Inc.
Phase 3
312
Alabama, Arkansas, Colorado, Florida, Illinois, New York, North Carolina, Tennessee
2026-09
Recruiting
Brexanolone Lifting Outcomes Of Moms
NCT07822321Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression
Lipocine Inc.
Phase 3
120
Arizona, California, Colorado, Georgia, Idaho, Illinois, Louisiana, Nevada
2026-09
Not yet open
WATER IV PCa (AS Sub-study)
NCT07650448Localized Prostate Cancer
PROCEPT BioRobotics
Not applicable
333
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Maryland
2026-09
Recruiting
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD
NCT07836647Post Traumatic Stress Disorder
DrugMethylone
Transcend Therapeutics
Phase 3
300
Colorado, Florida
2026-09
Recruiting
Vaginal Wall Retraction Using VuSleeve
NCT07846527Adult Females
Ceek Women's Health, INC
Observational
500
Colorado, Georgia
2026-09
Not yet open
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
NCT07817875Obesity
DrugTirzepatide
Eli Lilly and Company
Phase 3
150
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2026-09
Recruiting
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
NCT07720271Overweight, Obesity
DrugZenagamtide
Novo Nordisk A/S
Phase 3
950
Alabama, California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana
2026-08-31
Recruiting
PULmonary Stimulation for Asthma Relief
NCT07709754Moderate to Severe Asthma
Spiro Medical, Inc.
Not applicable
30
Colorado, Florida
2026-08-30
Recruiting
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
NCT07705555Diabetic Retinopathy, Macular Edema
DrugsTiespectus·Eylea·Aflibercept
Merck Sharp & Dohme LLC
Phase 3
960
California, Colorado, Florida, Maryland, New Jersey, New York, North Carolina, South Carolina
2026-08-27
Recruiting
A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation
NCT07527299Atrial Fibrillation
Biosense Webster, Inc.
Not applicable
1,070
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Kentucky, New York
2026-08-26
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2026-08-24
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993Chronic Kidney Disease
DrugElecoglipron
AstraZeneca
Phase 3
7,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-08-21
Recruiting
A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation
NCT07625215Atrial Fibrillation
Bayer
Phase 2
360
California, Colorado, Massachusetts, Michigan, North Carolina, Texas
2026-08-18
Recruiting
Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
NCT07288489Blood Loss, Surgical, Coagulation Disorder
VarmX B.V.
Phase 3
800
Arizona, California, Colorado, Delaware, Florida, Iowa, Massachusetts, Michigan
2026-08-18
Recruiting
Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)
NCT07654829Hereditary Angioedema
KalVista Pharmaceuticals, Ltd.
Phase 4
100
Colorado
2026-08-17
Recruiting
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
NCT07619131Hypercholesterolaemia
DrugsRosuvastatin 1·Rosuvastatin 2
AstraZeneca
Phase 3
600
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-08-12
Recruiting
Longevity Metrics AI/ML Development Study
NCT07808619Aging, Mortality, Cardiovascular Disease Prevention, Metabolic Syndrome
Longevity Metrics, Inc.
Observational
1,000,000
Colorado
2026-08-08
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07759245Pulmonary Disease, Chronic Obstructive
DrugBrenipatide
Eli Lilly and Company
Phase 2
606
Alabama, California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan
2026-08-07
Recruiting
Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation
NCT07335523Exocrine Pancreatic Insuficiency
Digestive Care, Inc.
Observational
30
Colorado, New York, Ohio, Oregon, Tennessee, Texas, Washington
2026-08-03
Recruiting
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07674654Acute Migraine
DrugElismetrep
Kallyope Inc.
Phase 3
1,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois
2026-08-03
Recruiting
A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
NCT07742735Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)
DrugApraglutide
VectivBio AG
Phase 3
124
California, Colorado, District of Columbia, Florida, Illinois, Kentucky, Michigan, New York
2026-08
Recruiting
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
NCT07745361Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma)
DrugsMRT-2359·Apalutamide
Monte Rosa Therapeutics, Inc
Phase 2
25
California, Colorado, Kansas, Maryland, Michigan, Nebraska, New Jersey, North Carolina
2026-08
Recruiting
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
NCT07520006B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsBexobrutideg·Obinutuzumab·Venetoclax·Rituximab
Nurix Therapeutics, Inc.
Phase 1/2
150
Colorado, Florida, Oregon, Pennsylvania, Tennessee, Texas
2026-08
Not yet open
Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer
NCT07675876Locally Advanced Non-Small Cell Lung Cancer, Lung Adenocarcinoma
DrugCromolyn Sodium
Carcinex Inc
Phase 1
10
Colorado
2026-08
Recruiting
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
NCT07697456Crohn's Disease, Ulcerative Colitis
DrugsTrosunilimab·ABBV-701·Risankizumab
AbbVie
Phase 2
2,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-07-31
Recruiting
Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease
NCT07348640Steno-occlusive Disease
DrugsGadopiclenol·Gadoterate meglumine
Guerbet
Phase 3
315
California, Colorado, Illinois, Minnesota, Texas, Washington
2026-07-28
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087Systemic Sclerosis
Boehringer Ingelheim
Phase 3
448
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Illinois, Louisiana
2026-07-27
Recruiting
Autus Valve Continued Access Study (CAS)
NCT07466745Congenital Heart Disease
Edwards Lifesciences
Not applicable
36
California, Colorado, Georgia, Massachusetts, Michigan, New York, North Carolina, Ohio
2026-07-27
Recruiting
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
NCT07681596Relapsed or Refractory Multiple Myeloma
DrugsAldesleukin·Daratumumab
AstraZeneca
Phase 1/2
101
California, Colorado, Florida, Georgia, Missouri, New Jersey, Ohio, Tennessee
2026-07-27
Recruiting
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680Solid Tumors
DrugsNavlimetostat·Pumitamig·Temozolomide·Cetuximab
Bristol-Myers Squibb
Phase 2
260
California, Colorado, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New York
2026-07-27
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
230
Colorado, Maryland, Michigan, New Jersey, New York, North Carolina, Ohio, Utah
2026-07-24
Recruiting
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT07383506PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer
Cogent Biosciences, Inc.
Phase 1
90
Arizona, California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Tennessee
2026-07-23
Recruiting
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
NCT07366034Fibrosing Interstitial Lung Disease
DrugNerandomilast
Boehringer Ingelheim
Phase 3
35
California, Colorado, Maryland, Massachusetts, Minnesota, Ohio, Pennsylvania
2026-07-21
Recruiting
Data Collection Study Using CS (CardiacSense) BP (Blood Pressure) Watch and Pillow Systems
NCT07749963Blood Pressure Monitoring
CardiacSense Ltd.
Not applicable
100
Colorado
2026-07-21
Recruiting
DBC-664 in Adult Patients With Solid Tumors
NCT07705035Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
Duboce Biopharmaceuticals, Inc.
Phase 1
210
Colorado, Michigan, New Jersey, New York, Tennessee, Texas
2026-07-17
Recruiting
MoblO2 to Maintain Oxygenation
NCT07704567COPD (Chronic Obstructive Pulmonary Disease), Intersitital Lung Disease
Minnesota HealthSolutions
Not applicable
48
Colorado
2026-07-09
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
NCT07664553Type 2 Diabetes Mellitus
DrugElecoglipron
AstraZeneca
Phase 3
600
Arkansas, California, Colorado, Florida, Georgia, Maryland, New York, North Carolina
2026-07-08
Recruiting
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
NCT07630974Malignant Neoplasm
DrugIfinatamab Deruxtecan
Merck Sharp & Dohme LLC
Phase 1/2
134
California, Colorado, Iowa, Massachusetts, Michigan, New Jersey, New York, North Dakota
2026-07-06
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
NCT07662044Type 2 Diabetes Mellitus
DrugsElecoglipron·Dapagliflozin
AstraZeneca
Phase 3
800
Alabama, California, Colorado, Connecticut, Florida, Georgia, Kansas, Kentucky
2026-07-06
Recruiting
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
NCT07426757Advanced Malignancies, Advanced Cancer
DrugMidazolam
Pfizer
Phase 1
120
Colorado, Florida, Georgia, Tennessee
2026-07-01
Recruiting
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07645924Migraine
DrugElismetrep
Kallyope Inc.
Phase 3
1,800
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois
2026-07-01
Recruiting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
NCT07536269Congenital Adrenal Hyperplasia
DrugCrinecerfont
Neurocrine Switzerland GmbH
Phase 2
20
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Michigan, Minnesota
2026-07-01
Recruiting
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
NCT07453888Non-Arteritic Anterior Ischemic Optic Neuropathy
DrugCenegermin
Dompé Farmaceutici S.p.A
Phase 3
272
California, Colorado, Florida, Georgia, Illinois, Kentucky, Maryland, Massachusetts
2026-07-01
Not yet open
Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Femoral Stenting (SKYWARD Trans-Femoral IDE [Investigational Device Exemption] Study)
NCT07512128Carotid Artery Calcification, Carotid Artery Diseases
Shockwave Medical, Inc.
Not applicable
185
Arizona, Colorado, Florida, Georgia, Louisiana, Missouri, New York, North Carolina
2026-07
Not yet open
Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage
NCT07218185Hypofibrinogenemia, Hemorrhage, Trauma Associated Hemorrhage, Hemorrhagic Shock
Cerus Corporation
Observational
320
Colorado, Florida, Maryland, Missouri
2026-07
Recruiting
An Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of North Star Desiccated Porcine Thyroid Extract Tablets.
NCT07747103Hypothyroidism
Neuvosyn Laboratories, LLC
Phase 3
466
California, Colorado, Florida, Idaho, Massachusetts, Nevada, North Carolina, South Carolina
2026-06-30
Recruiting
EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
NCT07523581Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive
Eloxx Pharmaceuticals, Inc.
Phase 2
24
California, Colorado, Minnesota, New Jersey, Pennsylvania, Texas
2026-06-30
Recruiting
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
NCT07684820Chronic Obstructive Pulmonary Disease (COPD)
Expedition Therapeutics, Inc
Phase 2
600
Arizona, California, Colorado, Florida, Georgia, Indiana, Kansas, Minnesota
2026-06-30
Recruiting
Detection of Atrial Fibrillation Using PPG From Smartphone Cameras
NCT07779213Atrial Fibrillation (AF)
Happitech BV
Observational
554
Arkansas, Colorado, Louisiana, Oklahoma
2026-06-30
Recruiting
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
NCT07589634Multiple Myeloma
DrugsRamantamig·Tocilizumab
Janssen Research & Development, LLC
Phase 2
230
Arizona, California, Colorado, Missouri
2026-06-30
Recruiting
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803Weight Management
DrugElecoglipron
AstraZeneca
Phase 3
4,500
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-06-29
Recruiting
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
NCT07671911Idiopathic Pulmonary Fibrosis
DrugNalbuphine
Trevi Therapeutics
Phase 3
306
California, Colorado, Florida, Louisiana, Missouri, North Carolina, Pennsylvania, South Carolina
2026-06-29
Recruiting
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
NCT07764978Newly Diagnosed Multiple Myeloma
DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab
AstraZeneca
Phase 3
750
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2026-06-26
Recruiting
A Study of Depemokimab in Participants of 6 to 11 Years of Age
NCT07671001Asthma
DrugDepemokimab
GlaxoSmithKline
Phase 3
34
Alabama, Colorado, South Dakota
2026-06-25
Recruiting
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
NCT07705334Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer
SHY Therapeutics
Phase 1
30
Arizona, Colorado, Texas
2026-06-24
Recruiting
Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension
NCT07511361Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
Kardigan, Inc.
Phase 2
140
Colorado, Florida, Illinois, Michigan, New York, Ohio, South Carolina, Tennessee
2026-06-23
By invitation
An Evaluation of the Long-Term Safety and Efficacy of TSND-201 for the Treatment of PTSD
NCT07670702Post Traumatic Stress Disorder
DrugMethylone
Transcend Therapeutics
Phase 3
300
Arkansas, California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Ohio
2026-06-22
Active, closed
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
NCT07702578AML, MDS
DrugTSC-101
TScan Therapeutics, Inc.
Phase 3
310
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas
2026-06-18
Recruiting
Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents
NCT07660198Pneumococcal Disease
DrugsPG4·Prevnar 20
Pfizer
Phase 3
1,200
Alabama, California, Colorado, Florida, Idaho, Kentucky, Louisiana, Massachusetts
2026-06-15
Recruiting
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1
NCT07645287HIV-1-infection
DrugsGS-3242·B/F/TAF·Lenacapavir
Gilead Sciences
Phase 2
175
Arizona, California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey
2026-06-15
Recruiting
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
NCT07365319Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
DrugsEIK1001·Cisplatin/Carboplatin·Nab-paclitaxel·Pemetrexed
Eikon Therapeutics
Phase 2/3
750
Alabama, California, Colorado, Florida, Illinois, New Mexico, New York, Tennessee
2026-06-15
Recruiting
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
NCT07309445Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Observational
150
Alabama, Arkansas, California, Colorado, Florida, Illinois, Indiana, Michigan
2026-06-12
Recruiting
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
NCT07646678Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
DrugTAK-360
Takeda
Phase 2/3
500
California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey, North Carolina
2026-06-11
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-06-11
Active, closed
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
DrugsCliramitug·Eplontersen
AstraZeneca
Phase 2
326
California, Colorado, District of Columbia, Florida, Illinois, Massachusetts, Missouri, New York
2026-06-11
Recruiting
Health Ahead Comparative Effectiveness Study
NCT07669168Health Services Accessibility, Rural Health, Medically Underserved Area, Preventive Health Services
William Brandenburg, MD
Not applicable
1,000,000
Colorado
2026-06-09
Active, closed
Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9
NCT07678775Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
DrugRibitol
ML Bio Solutions, Inc.
Phase 3
107
Arkansas, California, Colorado, Florida, Iowa, Kansas, Maryland, Minnesota
2026-06-05
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Immuneering Corporation
Phase 3
510
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2026-06-05
Recruiting
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy
NCT07675135EDS, Cataplexy, Fatigue, Narcolepsy
DrugPitolisant
Harmony Biosciences Management, Inc.
Phase 3
258
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-06-04
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Arizona, California, Colorado, Florida, Minnesota
2026-06-03
Recruiting
Study of ALK-001 on the Progression of Stargardt Disease
NCT07419334Stargardt Disease
DrugALK-001
Alkeus Pharmaceuticals, Inc.
Phase 3
230
Arizona, Colorado, Florida, Massachusetts, Michigan, Ohio, Pennsylvania, Texas
2026-06-03
Recruiting
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
NCT07586618Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia ALL
Allterum Therapeutics, Inc
Phase 1
24
Colorado, Indiana, New York, Ohio, Pennsylvania, Texas
2026-06-01
Recruiting
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07192952Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
117
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2026-06-01
Not yet open
Evaluation of the Efficacy, Safety, and Tolerability of LevoCept
NCT04457076Contraception, Women at Risk for Pregnancy
Sebela Women's Health Inc.
Phase 3
1,525
California, Colorado, Georgia, Hawaii, Indiana, Minnesota, Missouri, Nevada
2026-06-01
Recruiting
Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis
NCT07290140Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Airiver Medical, Inc.
Not applicable
300
Alabama, California, Colorado, Iowa, Kentucky, Pennsylvania, South Carolina, Texas
2026-06-01
Recruiting
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
NCT07592273Diabetic Retinopathy
DrugSurabgene Lomparvovec
AbbVie
Phase 2/3
576
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Maine
2026-06-01
Recruiting
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
NCT06712654Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis
R1 Therapeutics
Phase 2
168
Alabama, California, Colorado, Connecticut, Florida, Georgia, Michigan, Minnesota
2026-06-01
Not yet open
A Study of CS231295 in Patients With Advanced Solid Tumors
NCT07612488Advance Solid Tumors, Advanced Malignant Solid Tumors
ThalassaX Therapeutics United States Ltd
Phase 1
42
Colorado, Florida, Massachusetts, Tennessee
2026-06
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186Multiple Myeloma
DrugsRamantamig·Teclistamab
Janssen Research & Development, LLC
Phase 3
700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-31
Recruiting
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
NCT07598708Narcolepsy Type 1, Narcolepsy Type 2
Centessa Pharmaceuticals (UK) Limited
Phase 2/3
222
Alabama, Colorado, Florida, Georgia, Mississippi, North Carolina, Ohio, South Carolina
2026-05-29
Recruiting
Immune Modulation During Palynziq® Treatment in Adults (IMPALA)
NCT07477691Phenylketonuria
DrugsPegvaliase·Methotrexate
BioMarin Pharmaceutical
Phase 4
12
California, Colorado, Florida, Illinois, Indiana, Minnesota, New York, Oregon
2026-05-29
Recruiting
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.
NCT07629440Pneumococcal Disease
DrugsPG4·Prevnar 20
Pfizer
Phase 3
3,230
Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-05-29
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
California, Colorado, Connecticut, Illinois, Iowa, Kansas, Massachusetts, Michigan
2026-05-28
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
Apollo Therapeutics Ltd
Phase 2
280
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-05-28
Recruiting
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
NCT07614776Neovascular Age-related Macular Degeneration, nAMD
Amgen
Phase 3
304
California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland, Massachusetts
2026-05-27
Recruiting
The Impact of Enhanced Music & Natural Visuals on Emotional Health
NCT07676110Emotion Management Skills, Lifestyle, Healthy, Lifestyle Intervention, Recovery
soundBrilliance LLC
Not applicable
200
Colorado, Nebraska, Nevada
2026-05-25
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856Colitis, Ulcerative
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
644
California, Colorado, Florida, Georgia, Kentucky, Louisiana, Michigan, New York
2026-05-23
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT07525206Colorectal Cancer
DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab
AbbVie
Phase 3
990
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-05-22
Recruiting
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
NCT07479797Relapsed or Refractory Large B-cell Lymphoma
DrugsKITE-753·Axicabtagene Ciloleucel·Fludarabine·Cyclophosphamide
Kite, A Gilead Company
Phase 3
550
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Missouri
2026-05-22
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843Crohn Disease
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
460
California, Colorado, Florida, Georgia, Kentucky, Louisiana, Michigan, New York
2026-05-22
Recruiting
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414Obesity, Type 2 Diabetes
DrugsCagriSema·Semaglutide
Novo Nordisk A/S
Phase 3
2,500
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-05-21
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 2
350
Arizona, California, Colorado, Connecticut, Florida, Indiana, Kansas, Massachusetts
2026-05-20
Recruiting
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
NCT06948214Growth Hormone Deficiency (GHD)
DrugLUM-201
Lumos Pharma
Phase 3
150
Alabama, California, Colorado, District of Columbia, Florida, Indiana, Iowa, Louisiana
2026-05-20
Recruiting
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
NCT07541287IgA Nephropathy
DrugJADE101
Jade Biosciences, Inc.
Phase 2
30
California, Colorado, Florida, Texas
2026-05-19
Recruiting
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
NCT07416526Hemophilia A
Hoffmann-La Roche
Phase 3
138
Colorado, Iowa
2026-05-15
Recruiting
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
NCT07599670Alzheimer's Disease
AbbVie
Phase 1/2
210
California, Colorado, Florida, Massachusetts, Tennessee, Texas
2026-05-15
Recruiting
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
NCT07392892Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
DrugsPF-08634404·Nivolumab
Pfizer
Phase 2/3
840
California, Colorado, Florida, Illinois, Maryland, Nevada, New Jersey, New York
2026-05-14
Recruiting
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
NCT07387549Primary Sclerosing Cholangitis
DrugElafibranor
Ipsen
Phase 3
350
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-05-14
Recruiting
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
NCT07579702Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Insulet Corporation
Not applicable
200
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Massachusetts, Michigan
2026-05-13
Recruiting
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
NCT07287098Breast Neoplasms
DrugsImlunestrant·Goserelin·Tamoxifen
Eli Lilly and Company
Phase 2
600
Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Kentucky
2026-05-13
Recruiting
Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica
NCT07286214Polymyalgia Rheumatica
DrugSarilumab
Sanofi
Phase 4
300
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Missouri
2026-05-12
Recruiting
A Study to Assess the Safety, Tolerability and Efficacy of ION775
NCT07604974Hypertriglyceridemia, Severe Hypertriglyceridemia
Ionis Pharmaceuticals, Inc.
Phase 2
72
California, Colorado, Florida, Georgia, Indiana, Kentucky, Michigan, Ohio
2026-05-12
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001Obesity, Heart Failure
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
5,610
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2026-05-11
Recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263Cardiovascular Disease and Lipoprotein(a)
DrugPelacarsen
Novartis Pharmaceuticals
Phase 3
5,700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-11
Recruiting
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
NCT07566156Urothelial Cancer, Urinary Bladder Neoplasms
DrugsMitomycin C·Enfortumab Vedotin·Fluorouracil·Keytruda
Astellas Pharma Global Development, Inc.
Phase 3
390
California, Colorado, Delaware, Illinois, Indiana, Missouri, Ohio, Oregon
2026-05-11
Recruiting
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
NCT07592689Major Depressive Disorder
DrugDT120
Definium Therapeutics US, Inc.
Phase 3
165
Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri
2026-05-10
Recruiting
A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants
NCT07535034Gout
DrugDotinurad
Crystalys Therapeutics
Phase 2
90
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2026-05-08
Recruiting
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NCT07214532Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)
Natera, Inc.
Not applicable
725
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana
2026-05-08
Recruiting
A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
NCT07081997Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Ascendis Pharma Bone Diseases A/S
Phase 3
36
Colorado, Illinois, Minnesota, Nevada, New York, North Carolina, Texas, Washington
2026-05-07
Recruiting
A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT05199688Neuromyelitis Optica Spectrum Disorder, NMOSD
DrugSatralizumab
Hoffmann-La Roche
Phase 3
8
Colorado
2026-05-06
Recruiting
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
NCT07318597Pulmonary Arterial Hypertension (PAH)
Regeneron Pharmaceuticals
Phase 2
99
Colorado, Massachusetts, Nebraska, Ohio
2026-05-06
Recruiting
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412Metastatic Colorectal Cancer
DrugsTrifluridine/Tipiracil·Bevacizumab
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Colorado, Florida, Illinois, Michigan, Minnesota, Missouri, New York, Tennessee
2026-05-06
Recruiting
Continuous Observational Monitoring Program for Allay™ Hydrogel Cap Safety and Success Study
NCT07246980Peripheral Nerve Injuries
Tulavi Therapeutics,Inc.
Observational
1,000
California, Colorado, Florida, Texas
2026-05-06
Recruiting
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
NCT07509151Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
DrugSurovatamig
AstraZeneca
Phase 3
420
California, Colorado, Connecticut, Illinois, Kansas, Kentucky, Maryland, Massachusetts
2026-05-05
Recruiting
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
NCT07513376Non-small Cell Lung Cancer
DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene
Merck Sharp & Dohme LLC
Phase 3
876
California, Colorado, Connecticut, Illinois, Missouri, Montana, Nebraska, Nevada
2026-05-04
Recruiting
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
NCT07611110Metastatic Castration-resistant Prostate Cancer
DrugsXofigo·FPI-2265·Cabazitaxel·Zytiga
AstraZeneca
Phase 3
670
Alabama, Arizona, California, Colorado, Florida, Illinois, Louisiana, Michigan
2026-05-04
Recruiting
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
NCT07483099Crohn Disease
DrugsLY4395089·Mirikizumab
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
Recruiting
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
NCT07483073Colitis, Ulcerative, Crohn Disease
DrugsLY4395089·Mirikizumab
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
Recruiting
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
NCT07519772Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
DrugMK-1045
Merck Sharp & Dohme LLC
Phase 1/2
280
Colorado, Tennessee
2026-05-03
Not yet open
Occlutech AFR Fontan Study
NCT07532369Failure of Fontan Type Circulation, Fenestration, Univentricular Heart, Congenital Anomaly
Occlutech International AB
Observational
25
Alabama, California, Colorado, Illinois, North Carolina, Texas
2026-05-01
Not yet open
Hearing Outcomes With the Nucleus® 8 Sound Processor and Nucleus® 7 Sound Processor in Adult Veteran and Non-veteran Cochlear Implant Recipients
NCT07582198Hearing Loss
Cochlear
Not applicable
26
Colorado
2026-05
Recruiting
Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes
NCT07521475Type 2 Diabetes Mellitus
Insulet Corporation
Not applicable
350
California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana, Massachusetts
2026-04-30
Recruiting
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
NCT07469891Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Post-Polycythemia Vera Myelofibrosis
Prelude Therapeutics Incorporated
Phase 1
100
California, Colorado, Florida, Michigan, Pennsylvania, Tennessee, Texas
2026-04-29
Recruiting
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
NCT07493512Metastatic Castration-resistant Prostate Cancer (mCRPC)
DrugXaluritamig
Amgen
Phase 1
40
Colorado, North Carolina, Ohio, Pennsylvania, South Dakota, Tennessee, Texas, Virginia
2026-04-28
Recruiting
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
NCT07416604Hemophilia A
DrugEmicizumab
Hoffmann-La Roche
Phase 3
360
California, Colorado, Florida, Indiana, Iowa, Washington
2026-04-27
Recruiting
Human Observatory Study
NCT07646782Aging, Mortality, All-cause Mortality, Life Expectancy
Longevity Metrics, Inc.
Observational
1,000,000
Colorado
2026-04-25
Recruiting
Phase 2 Study to Assess the Safety and Efficacy of ANG003
NCT07450547Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Anagram Therapeutics, Inc.
Phase 2
113
California, Colorado, Florida, Illinois, Iowa, Kansas, Kentucky, Maine
2026-04-24
By invitation
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
NCT07393373Hypochondroplasia
DrugInfigratinib
QED Therapeutics, a BridgeBio company
Phase 2
135
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2026-04-23
Recruiting
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
NCT07365332Pulmonary Arterial Hypertension
Inhibikase Therapeutics
Phase 3
486
Arizona, California, Colorado, Kansas, Kentucky, Massachusetts, Missouri, New York
2026-04-23
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)
Liquidia Technologies, Inc.
Phase 3
344
Arizona, California, Colorado, Florida, Illinois, Indiana, New York, Oregon
2026-04-23
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995Metastatic Castration-resistant Prostate Cancer
DrugsBNT324·Prednisone/Prednisolone·Docetaxel
BioNTech SE
Phase 3
736
California, Colorado, Florida, Illinois, Maryland, New York, Ohio, Tennessee
2026-04-22
Recruiting
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
NCT07611214Lupus Nephritis
DrugsLupkynis·Anifrolumab
Aurinia Pharmaceuticals Inc.
Phase 4
150
California, Colorado, Florida, Georgia, Louisiana, Maryland, Missouri, Nevada
2026-04-22
Recruiting
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
NCT07502443Narcolepsy Type 2
DrugAlixorexton
Alkermes, Inc.
Phase 3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts
2026-04-22
Recruiting
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
NCT07558733HR+ HER2- Breast Cancer
DrugsSerabelisib·Sapanisertib·Fulvestrant
Faeth Therapeutics
Phase 1/2
32
California, Colorado, Oregon, Tennessee, Texas
2026-04-22
Recruiting
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232Crohn Disease
DrugsRisankizumab·Guselkumab
Janssen Research & Development, LLC
Phase 3
530
Alabama, California, Colorado, Connecticut, Florida, Georgia, Iowa, Kansas
2026-04-21
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181Systemic Lupus Erythematosus
DrugBI 3000202
Boehringer Ingelheim
Phase 2
405
California, Colorado, Florida, Michigan, Mississippi, Montana, North Carolina, Ohio
2026-04-20
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Minnesota, New York
2026-04-17
Recruiting
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
NCT07287670Diffuse Cutaneous Systemic Sclerosis
Mediar Therapeutics
Phase 2
85
Arizona, California, Colorado, Florida, Kansas, Maryland, Massachusetts, Minnesota
2026-04-16
Recruiting
A Clinical Study Evaluating Licaminlimab for Dry Eye Disease
NCT07548632Dry Eye Disease (DED)
Oculis
Phase 2/3
160
California, Colorado, Florida, North Carolina, Pennsylvania, Tennessee, Virginia
2026-04-16
Recruiting
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
NCT07264959Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Observational
150
Colorado, Illinois, Maryland, Massachusetts, Michigan, Missouri, Utah
2026-04-15
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
NCT07496567Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
DrugsTiespectus·Eylea·Aflibercept
EyeBiotech Ltd.
Phase 2/3
960
Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa, Kansas
2026-04-15
Recruiting
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
NCT07158242Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
100
Colorado, Florida, Georgia, New York
2026-04-15
Recruiting
OBPM_PANDA2026: Evaluation of the Performance and Safety of the Aktiia Periodic Optical Blood Pressure Monitoring Device
NCT07507903Hypertension
Aktiia SA
Not applicable
200
Colorado
2026-04-14
Recruiting
Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
NCT06964087Type I Diabetes
DrugOPT101
Op-T LLC
Phase 2
72
Alabama, California, Colorado, Illinois, Washington
2026-04-10
Recruiting
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073Solid Tumors
DrugINCB161734
Incyte Corporation
Phase 3
588
Alabama, Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia
2026-04-09
Recruiting
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
NCT07519655Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma
Pfizer
Phase 1
250
Colorado, Connecticut, Tennessee, Virginia
2026-04-08
Recruiting
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
NCT07519395Irritable Bowel Syndrome
DrugCamlipixant
GlaxoSmithKline
Phase 2
420
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-04-08
Recruiting
A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation
NCT07535112Advanced/Metastatic Colorectal Adenocarcinoma
DrugCetuximab
Bayer
Phase 1
130
Arizona, California, Colorado, New York, Texas
2026-04-07
Recruiting
A Gaucher Disease Gene Therapy Trial With FLT201
NCT07223944Gaucher Disease Type 1
Spur Therapeutics
Phase 3
45
California, Colorado, Georgia, Iowa, Minnesota, New Jersey, New York, North Carolina
2026-04-07
Recruiting
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
NCT07424404Schizophrenia, Autism-Related Irritability
DrugsKarX-EC·KarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
400
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-04-07
Recruiting
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
NCT07455383Narcolepsy Type 1
DrugAlixorexton
Alkermes, Inc.
Phase 3
150
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts
2026-04-06
Active, closed
A Pivotal Study to Evaluate the Clinical Benefit, Performance and Safety of a Totally Implantable Cochlear Implant (TICI) System in Adults
NCT07287124Hearing Loss, Bilateral Sensorineural
Cochlear
Not applicable
56
Colorado, Florida, Iowa, Michigan, Minnesota, Missouri, New York, Ohio
2026-04-03
Recruiting
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
NCT07456696Post Traumatic Stress Disorder
DrugMethylone
Transcend Therapeutics
Phase 3
300
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Louisiana
2026-04-02
Recruiting
Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung
NCT07499674Lung Cancer, Lung Metastases
Vergent Bioscience, Inc.
Phase 3
132
California, Colorado, Florida, Michigan, Minnesota, Pennsylvania, Texas
2026-03-31
Recruiting
Combined OFM and Vacuum-assisted Therapy for Expedited Regeneration Over Structures
NCT07385313Soft Tissue Defects, Soft Tissue Wounds, Traumatic Soft Tissue Defect
Aroa Biosurgery Limited
Phase 4
30
Colorado, Texas
2026-03-31
By invitation
Okami Medical ALPHA Registry
NCT07525518Arterial Bleed, Pulmonary Arteriovenous Malformation, Embolization, Hemorrhage
Okami Medical, Inc.
Observational
500
Colorado, Massachusetts, North Carolina
2026-03-31
Recruiting
A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
NCT07549321High-Risk Neuroblastoma
DrugsTemozolomide·Irinotecan
Renaissance Pharma Ltd.
Phase 2/3
144
Colorado, Minnesota, New York, North Carolina, Pennsylvania
2026-03-30
Recruiting
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
NCT07199465Cytomegalovirus Prophylaxis
DrugLetermovir
Merck Sharp & Dohme LLC
Phase 1
40
Alabama, California, Colorado, Florida, Georgia, Illinois, Michigan, Minnesota
2026-03-30
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana
2026-03-26
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906Immunoglobulin A Nephropathy (IgAN)
DrugZigakibart
Novartis Pharmaceuticals
Phase 2
32
Colorado, Georgia, Iowa, Minnesota
2026-03-26
Recruiting
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
NCT07463183Colitis Ulcerative, Ulcerative Colitis
Merck Sharp & Dohme LLC
Phase 2
100
California, Colorado, Florida, Georgia, Kansas, Louisiana, Missouri
2026-03-24
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
NCT07326709Huntington Disease
DrugVotoplam
Novartis Pharmaceuticals
Phase 3
770
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-03-24
Recruiting
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
NCT07355296Proteinuric Kidney Diseases
DrugApecotrep
Boehringer Ingelheim
Phase 2
132
Alabama, California, Colorado, Florida, Illinois, Maryland, Michigan, New York
2026-03-23
By invitation
Evaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate (MF)
NCT07286201Chronic Rhinosinusitis (CRS), Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Polyganics BV
Not applicable
110
Colorado, Georgia, Illinois, Louisiana, Maryland, South Carolina, Texas, Utah
2026-03-19
Recruiting
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
NCT07532603Lichen Planopilaris
DrugBrepocitinib
Priovant Therapeutics, Inc.
Phase 2/3
342
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2026-03-19
Recruiting
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
NCT07387367Adenovirus Infections
SymBio Pharmaceuticals
Phase 3
180
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2026-03-17
Recruiting
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
NCT07473778HIV Infections
DrugsF/TAF·Emtricitabine/tenofovir disoproxil fumarate·Descovy·F/TDF
Gilead Sciences
Observational
3,000
Alabama, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2026-03-17
Recruiting
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
NCT07482176Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
DrugAflibercept
Adverum Biotechnologies, Inc.
Phase 3
534
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-03-16
Recruiting
BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System
NCT07118358Leadless Pacemaker, Bradycardia, AV Block, Cardiac Rhythm Disorder
Biotronik, Inc.
Not applicable
325
California, Colorado, Florida, Kentucky, Michigan, Minnesota, Missouri, New York
2026-03-16
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497Non-small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Durvalumab
Bristol-Myers Squibb
Phase 3
850
Alabama, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Kentucky
2026-03-16
Recruiting
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
NCT07143019Hemorrhagic Stroke, Aneurysm, Intracranial, Saccular Aneurysm, Fusiform Aneurysm
phenox Inc.
Not applicable
214
Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa, Massachusetts
2026-03-16
Recruiting
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)
NCT07500090Idiopathic Hypersomnia
DrugPitolisant
Harmony Biosciences Management, Inc.
Phase 3
248
Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Michigan
2026-03-16
Recruiting
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
NCT07456033Asthma
DrugDepemokimab
GlaxoSmithKline
Phase 3
456
Arkansas, California, Colorado, Florida, Louisiana, Oklahoma, Pennsylvania, South Dakota
2026-03-13
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Pembrolizumab
Bristol-Myers Squibb
Phase 3
750
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-03-12
Recruiting
Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis
NCT07339111Knee Cartilage Defects
Medipost, Inc.
Phase 3
300
Alabama, Arizona, California, Colorado, Illinois, Kentucky, Louisiana, Michigan
2026-03-11
Recruiting
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
NCT07421700Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma
DrugsPF-08634404·Enfortumab Vedotin
Pfizer
Phase 1/2
132
Arkansas, California, Colorado, Connecticut, District of Columbia, Georgia, Illinois, Maryland
2026-03-11
Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
1,182
Arizona, California, Colorado, Florida, Maryland, Ohio, Tennessee, Texas
2026-03-11
Recruiting
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
NCT07491497ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer
TRIANA Biomedicines, Inc.
Phase 1/2
160
California, Colorado, Massachusetts, Missouri, New York, North Carolina, Ohio, Pennsylvania
2026-03-11
Recruiting
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
NCT07584226Advanced NRAS-Mutant Melanoma, Advanced NRAS-Mutant Solid Tumors, NRAS Mutation, NRAS G12D
Relay Therapeutics, Inc.
Phase 1
35
California, Colorado, Massachusetts, Michigan, New York, Tennessee, Virginia
2026-03-09
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849CRC (Colorectal Cancer)
DrugsINCA33890·Folfox·Bevacizumab
Incyte Corporation
Phase 3
700
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-03-05
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496Lupus Erythematosus, Systemic
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
600
California, Colorado, Florida, Georgia, Illinois, Louisiana, Michigan, New Jersey
2026-03-05
Recruiting
TOUCH® CMC 1 New Enrollment US Study
NCT07405983Osteoarthritis Thumb, Thumb Carpometacarpal Joint Osteoarthritis
Keri Medical SA
Observational
163
Colorado, Indiana, North Carolina, Texas
2026-03-04
Recruiting
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
NCT07409246Multiple Myeloma
AbbVie
Phase 1
127
California, Colorado, Florida, Georgia, Illinois, Michigan
2026-02-27
Recruiting
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
NCT07325526Liver Cirrhosis
Boehringer Ingelheim
Phase 2
30
Arizona, California, Colorado, Florida, Georgia, Iowa, Kansas, Maryland
2026-02-27
By invitation
Persona SoluTion PPS Femur PMCF
NCT07286513Rhematoid Arthritis, Osteo Arthritis of the Knee, Traumatic Arthritis of Knee (Diagnosis), Polyarthritis
Zimmer Biomet
Observational
200
Colorado, Kentucky, Maryland
2026-02-26
Recruiting
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
NCT07404865Primary Sjogren's Disease
DrugTelitacicept
Vor Biopharma
Phase 3
250
Arizona, California, Colorado, Florida, Idaho, Illinois, Louisiana, Maryland
2026-02-26
Recruiting
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
NCT07168993Lung Cancer (Diagnosis)
bioAffinity Technologies Inc.
Not applicable
2,063
California, Colorado, Florida, Illinois, Ohio, Pennsylvania, Texas, Wisconsin
2026-02-25
Recruiting
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
NCT07432958Parkinson Disease
Appello Pharmaceuticals, Inc.
Phase 2
150
Arkansas, California, Colorado, Florida, Georgia, Indiana, Kansas, Kentucky
2026-02-25
Active, closed
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2
DrugBerobenatide
Pfizer
Phase 3
1,078
California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska, New Jersey
2026-02-24
Recruiting
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT07503808Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
IDEAYA Biosciences
Phase 1
150
Colorado, Florida, Michigan, New York, Tennessee, Texas, Utah, Virginia
2026-02-24
Recruiting
REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool
NCT07280065PTSD - Post Traumatic Stress Disorder
Senseye, Inc.
Phase 3
1,900
Colorado, Georgia, Idaho, Massachusetts, South Carolina
2026-02-23
Recruiting
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07391657Relapsed Refractory Multiple Myeloma
DrugsAZD0120·Darzalex·Velcade·Carfilzomib
AstraZeneca
Phase 3
508
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-02-23
Active, closed
AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction
NCT07368959Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)
Aurion Biotech
Phase 3
130
Arizona, Arkansas, Colorado, Georgia, Missouri, North Carolina, Pennsylvania, South Carolina
2026-02-19
Recruiting
A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
NCT07409103Active Rheumatoid Arthritis
Elevara Medicines Limited
Phase 2
180
Arizona, California, Colorado, Florida, Louisiana, Michigan, North Carolina, Pennsylvania
2026-02-18
Recruiting
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT07335497Locally Advanced / Metastatic Solid Tumors
Crescent Biopharma, Inc.
Phase 1/2
290
Alabama, California, Colorado, District of Columbia, Florida, Michigan, New York, Ohio
2026-02-17
Active, closed
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449936Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
DrugsEYP-1901·Aflibercept
EyePoint Pharmaceuticals, Inc.
Phase 3
240
California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana, Louisiana
2026-02-16
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
DrugApecotrep
Boehringer Ingelheim
Phase 3
286
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2026-02-16
Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546HIV Infections
DrugsVH4524184·Dovato·Dolutegravir/Lamivudine
ViiV Healthcare
Phase 2
186
California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky, Missouri
2026-02-11
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
800
Alabama, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan
2026-02-10
Recruiting
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
NCT07201922Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
80
California, Colorado, Florida, Kansas, Massachusetts, Michigan, Minnesota, New York
2026-02-10
Recruiting
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT07227415Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm
DrugsCasdatifan·PF-08634404·Axitinib·Yervoy
Pfizer
Phase 1/2
224
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts
2026-02-10
Active, closed
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related Cataract
NCT07395986Age Related Cataracts
Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.
Phase 2
8
Arizona, California, Colorado, Florida, Georgia, Illinois, North Carolina, North Dakota
2026-02-10
Recruiting
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931Osteoarthritis, Overweight or Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
900
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-02-09
Active, closed
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449923Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
DrugsEYP-1901·Aflibercept
EyePoint Pharmaceuticals, Inc.
Phase 3
240
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Kentucky
2026-02-09
Recruiting
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout
NCT07388498Uncontrolled Gout
DrugMethotrexate
Amgen
Phase 3
270
Alabama, Alaska, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-02-09
Active, closed
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441Multiple Myeloma
DrugRamantamig
Janssen Research & Development, LLC
Phase 2
168
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2026-02-08
Recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia
NCT07304089Dystonia
DrugVIM0423
Vima Therapeutics
Phase 2
100
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2026-02-05
Recruiting
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07222332Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
300
Colorado, Florida, Pennsylvania, Texas, Virginia
2026-02-05
Recruiting
A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
NCT07372625TP53 Y220C Mutation, Advanced Solid Tumors
DrugsRezatapopt·Repaglinide·Midazolam Hydrochloride·Metformin Hydrochloride
PMV Pharmaceuticals, Inc
Phase 1
14
Colorado, Florida, Tennessee, Texas
2026-02-04
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511Multiple Myeloma
DrugsRamantamig·Teclistamab
Janssen Research & Development, LLC
Phase 3
400
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-02-04
Recruiting
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
NCT07224321Type 1 Diabetes Mellitus
Mannkind Corporation
Phase 2
100
California, Colorado, Connecticut, Florida, Indiana, Massachusetts, Oklahoma, Texas
2026-02-04
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin
AstraZeneca
Phase 3
2,130
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2026-02-03
Recruiting
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
NCT07223203Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN
DrugsNucresiran·Vutrisiran
Alnylam Pharmaceuticals
Phase 3
125
Colorado, Illinois, Maryland, Massachusetts, Minnesota, New York, North Carolina, Tennessee
2026-02-03
Active, closed
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
NCT07228117Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Medtronic MiniMed, Inc.
Not applicable
389
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois
2026-02-02
Recruiting
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
NCT06968845Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics
Phase 2
120
Alabama, California, Colorado, Connecticut, Florida, Indiana, Kansas, Michigan
2026-02-02
Recruiting
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
NCT07322003Amyotrophic Lateral Sclerosis
DrugPridopidine
Prilenia
Phase 3
500
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Maryland
2026-02-01
Recruiting
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
NCT07422675PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease
Serina Therapeutics
Phase 1
40
Colorado, Florida, Michigan
2026-02-01
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
DrugsSigvotatug vedotin·PF-08634404
Pfizer
Phase 1/2
162
Arkansas, California, Colorado, Florida, New Jersey, New York, Oregon, Texas
2026-01-30
Recruiting
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
NCT07227597Small Cell Lung Cancer Extensive Stage
DrugsGocatamig·Ifinatamab Deruxtecan·Etoposide·Atezolizumab
Merck Sharp & Dohme LLC
Phase 1/2
170
California, Colorado, Florida, Kentucky, Missouri, New Jersey, Oregon, South Dakota
2026-01-29
Recruiting
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
NCT07323654Eosinophilic Asthma
DrugKT-621
Kymera Therapeutics, Inc.
Phase 2
264
California, Colorado, Connecticut, Florida, Georgia, Iowa, Kansas, Kentucky
2026-01-28
By invitation
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
NCT07286006Graves' Disease
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
372
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Indiana
2026-01-26
Recruiting
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
NCT07287917Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
DrugsDifluoromethylornithine·DFMO·Capivasertib·Fulvestrant
Aminex Therapeutics, Inc.
Phase 1/2
92
Arizona, California, Colorado, Kansas, Michigan, Minnesota, New York, Ohio
2026-01-26
Recruiting
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190Uveal Melanoma
DrugDarovasertib
IDEAYA Biosciences
Phase 3
520
Arizona, California, Colorado, Florida, Maryland, Massachusetts, Michigan, Minnesota
2026-01-25
Recruiting
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184944Crohn's Disease
DrugDuvakitug
Sanofi
Phase 3
751
Colorado, Florida, Illinois, Indiana, Louisiana, Missouri, New York, North Carolina
2026-01-22
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231Chronic Lymphocytic Leukemia
DrugsSonrotoclax·Venclyxto·Acalabrutinib·Venclexta
BeOne Medicines
Phase 3
500
California, Colorado, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Nebraska
2026-01-22
Recruiting
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
NCT07230834Geographic Atrophy (GA)
DrugPozelimab
Regeneron Pharmaceuticals
Phase 1
54
Colorado, Massachusetts, Texas
2026-01-19
Recruiting
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07185009Ulcerative Colitis
DrugDuvakitug
Sanofi
Phase 3
751
Arizona, California, Colorado, Florida, Indiana, Louisiana, Michigan, Missouri
2026-01-16
Recruiting
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
NCT07235293Colorectal Cancer
DrugsDSP107·Fruquintinib·Atezolizumab
Kahr Bio Australia Pty Ltd
Phase 2
90
Colorado, Florida, North Carolina, Pennsylvania, Texas
2026-01-16
Recruiting
Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study
NCT07114718Congenital Heart Disease, Congenital Heart Disease (CHD)
Starlight Cardiovascular Inc
Not applicable
45
California, Colorado, Massachusetts, Ohio, Pennsylvania, Texas, Washington
2026-01-16
Active, closed
A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
NCT07298330Chronic Hepatitis D Infection
DrugBulevirtide
Mirum Pharmaceuticals, Inc.
Phase 3
80
California, Colorado, Nevada, Ohio, Texas, Utah
2026-01-14
Recruiting
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292Multiple Sclerosis
DrugsMRI contrast-enhancing preparations·Frexalimab
Sanofi
Phase 3
160
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland
2026-01-14
Recruiting
A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis
NCT07355062CKD, Metabolic Acidosis
Renibus Therapeutics, Inc.
Phase 3
150
California, Colorado, Delaware, Florida, Georgia, Idaho, Illinois, Indiana
2026-01-13
Recruiting
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
NCT07382167Chronic Idiopathic Constipation (CIC)
DrugTenapanor
Ardelyx
Phase 3
692
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-01-13
Recruiting
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
NCT07188558Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
DrugsRondecabtagene autoleucel·Axi-cel·Breyanzi·Lisocabtagene maraleucel
Lyell Immunopharma, Inc.
Phase 3
400
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2026-01-12
Active, closed
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
NCT07365826Pneumococcal Vaccines
Drug31-valent pneumococcal conjugate vaccine
Vaxcyte, Inc.
Phase 3
1,390
Arizona, Colorado, Florida, Indiana, Kansas, Kentucky, Michigan, Nebraska
2026-01-12
Recruiting
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
NCT07301255Asthma
DrugENV-294
Enveda Therapeutics
Phase 2
50
Alabama, California, Colorado, Florida, Georgia, Illinois, Kansas, Kentucky
2026-01-09
Active, closed
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
NCT07285694Metastatic Castration Resistant Prostate Cancer (mCRPC)
Arsenal Biosciences, Inc.
Phase 1/2
190
California, Colorado, Iowa, Kansas, Minnesota, New York, Washington
2026-01-09
Recruiting
A Study of Buntanetap in Participants With PD
NCT07284784Parkinson's Disease (PD), Deep Brain Stimulation
DrugBuntanetap/posiphen
Annovis Bio Inc.
Phase 2/3
500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana
2026-01-09
Recruiting
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT07095452Multiple Myeloma
DrugsEtentamig·Daratumumab·Lenalidomide·Dexamethasone
AbbVie
Phase 2/3
680
Arizona, California, Colorado, Georgia, Indiana, Minnesota, New York, North Carolina
2026-01-08
By invitation
Lead Evaluation for Defibrillation and Reliability Post Approval Study
NCT07005232Tachyarrhythmia
Medtronic
Observational
2,000
Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Indiana
2026-01-07
Recruiting
Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease
NCT07378644Huntington Disease
DrugSKY-0515
Skyhawk Therapeutics, Inc.
Phase 2/3
400
Colorado
2026-01-06
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
NCT07219043Microvascular Inflammation
DrugFelzartamab
Biogen
Phase 2
81
California, Colorado, Kansas, Michigan, Minnesota, Missouri, Nebraska, New Jersey
2026-01-05
Recruiting
Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
NCT07224581GRIN-related Neurodevelopmental Disorder
DrugRadiprodil
GRIN Therapeutics, Inc.
Phase 3
100
California, Colorado, District of Columbia, Florida, Iowa, Massachusetts, New Jersey, New York
2026-01-05
Recruiting
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
NCT07217587Myasthenia Gravis
DrugsEfgartigimod·Nipocalimab
Janssen Research & Development, LLC
Phase 3
115
California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana, Massachusetts
2026-01-05
Recruiting
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
NCT07282587Advanced Pheochromocytoma and Paraganglioma, PCPG
DrugONC206
Jazz Pharmaceuticals
Phase 2
90
California, Colorado, Michigan, Minnesota, Missouri, New York, Pennsylvania, Utah
2026-01-02
Recruiting
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
NCT07335601MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugResmetirom
Madrigal Pharmaceuticals, Inc.
Phase 2
120
California, Colorado, District of Columbia, Illinois, Minnesota, Nebraska, New York, Tennessee
2025-12-29
Recruiting
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
NCT07104565Immune Thrombocytopenia
Incyte Corporation
Phase 2
56
Arizona, California, Colorado, Connecticut, Florida, Massachusetts, New York, Virginia
2025-12-29
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336Breast Neoplasms, Neoplasm Metastasis
DrugsTersolisib·Exemestane·Anastrozole·Abemaciclib
Eli Lilly and Company
Phase 3
800
Alaska, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-12-22
Recruiting
A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta
NCT07078383Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic
Vascutek Ltd.
Not applicable
150
California, Colorado, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Missouri
2025-12-19
Active, closed
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850Obesity and Overweight
DrugBerobenatide
Pfizer
Phase 3
3,578
Arizona, California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska
2025-12-19
Recruiting
Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome
NCT07135050Pitt Hopkins Syndrome
Mahzi Therapeutics
Phase 1/2
12
California, Colorado, Illinois
2025-12-19
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946Prostatic Neoplasms, Castration-Resistant
DrugsPasritamig·Prednisone/Prednisolone·Docetaxel
Janssen Research & Development, LLC
Phase 3
800
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-12-19
Recruiting
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
NCT07266831Human Immunodeficiency Virus Type 1 (HIV-1) Infection
DrugB/F/TAF
Merck Sharp & Dohme LLC
Phase 2/3
570
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan, Missouri
2025-12-18
Recruiting
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
NCT07284875Obesity, Overweight
DrugRibupatide
Kailera
Phase 3
2,340
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-12-18
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing
DrugFurmonertinib
ArriVent BioPharma, Inc.
Phase 3
480
California, Colorado, Illinois, Michigan, New York, Ohio, Pennsylvania, Texas
2025-12-17
Recruiting
Study of DONQ52 in Active Celiac Disease
NCT07239336Celiac Disease
Chugai Pharmaceutical
Phase 2
92
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Louisiana
2025-12-16
Recruiting
A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
NCT07228247Solid Tumors, Adult
Hutchmed
Phase 1/2
147
Colorado, Florida, New Jersey, New York, Ohio, Washington
2025-12-16
Recruiting
Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants
NCT07117669Peanut Allergy
N-Fold, LLC
Phase 1/2
68
Colorado
2025-12-16
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
1,035
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-12-15
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 3
500
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-12-15
Recruiting
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
NCT07276581Rheumatoid Arthritis
AstraZeneca
Phase 2
320
Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2025-12-15
Recruiting
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
NCT07221851Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Ascendis Pharma A/S
Phase 3
186
California, Colorado, Delaware, District of Columbia, Florida, Georgia, Idaho, Louisiana
2025-12-12
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Idaho
2025-12-12
Recruiting
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
NCT06947928Advanced Or Metastatic Merkel Cell Carcinoma
DrugsIFx-Hu2.0·Keytruda·Pembrolizumab
TuHURA Biosciences, Inc.
Phase 2/3
118
California, Colorado, Florida, Massachusetts, Minnesota, New Jersey, North Carolina, Pennsylvania
2025-12-11
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site
DrugsPF-08634404·Avastin·Bevacizumab
Pfizer
Phase 3
800
Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-12-11
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 3
150
California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan, Minnesota
2025-12-11
Recruiting
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559Breast Cancer, Metastatic
DrugsEvorpacept·Eribulin·Herceptin·Vinorelbine
ALX Oncology Inc.
Phase 2
120
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Michigan, Minnesota
2025-12-10
Active, closed
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
NCT07300839COVID-19, SARS-COV-2 Infection
DrugBNT162b2 Vaccine
BioNTech SE
Phase 3
5,240
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2025-12-10
Recruiting
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
NCT07290036Psoriatic Arthritis, Axial Spondyloarthritis
UCB Biopharma SRL
Phase 1
392
Arizona, California, Colorado, Florida, Illinois, Michigan, New Jersey, New Mexico
2025-12-10
Recruiting
Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support
NCT06910943Choline Deficiency, Liver Injury
Protara Therapeutics
Phase 2/3
129
Colorado, Florida, Illinois, Nebraska, New York, North Carolina, Ohio, Texas
2025-12-10
Recruiting
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
NCT07224373Multiple Sclerosis
AstraZeneca
Phase 1
24
Arizona, Colorado, District of Columbia, Missouri, New York, Ohio, Washington, Wisconsin
2025-12-09
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779Ovarian Cancer
DrugINCB123667
Incyte Corporation
Phase 3
466
Alaska, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2025-12-09
Active, closed
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT07287189Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases
DrugSAT-3247
Satellos Bioscience, Inc.
Phase 2
51
California, Colorado, Illinois, Massachusetts, Missouri, Ohio, Washington
2025-12-08
Recruiting
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
NCT07287033Peanut Allergies
Mabylon AG
Phase 1
48
Arkansas, Colorado, Florida, Massachusetts, Michigan, Texas
2025-12-06
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab
AstraZeneca
Phase 3
1,100
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-12-04
Recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453Plaque Psoriasis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
366
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Indiana
2025-12-03
Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
NCT07218926Gastrointestinal Neoplasms
DrugsIDRX-42·Sunitinib
GlaxoSmithKline
Phase 3
450
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Iowa
2025-12-03
Recruiting
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
NCT07268638Focal Segmental Glomerulosclerosis
Akebia Therapeutics
Phase 2
60
California, Colorado, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan
2025-12-03
Recruiting
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
NCT07276724Severe Asthma
DrugGB-0895
Generate Biomedicines
Phase 3
786
California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan, Mississippi
2025-12-03
Recruiting
Observational Study of Patients Undergoing Diagnostic Right Heart Catheterization
NCT07224906Pulmonary Hypertension, Congestive Heart Failure(CHF), Valve Disease, Heart
HemoCept Inc.
Observational
50
Colorado
2025-12-01
Not yet open
OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis
NCT06669403Sepsis, Community Acquired Pneumonia (CAP)
DrugOPT101
Op-T LLC
Phase 1
26
Colorado
2025-12
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146Small-cell Lung Cancer
DrugZL-1310
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
California, Colorado, Connecticut, Florida, Illinois, Iowa, Kentucky, Maryland
2025-11-30
Recruiting
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
NCT07144852Actinic Keratosis
Sun Pharmaceutical Industries, Inc.
Phase 3
260
Arizona, California, Colorado, Florida, Idaho, Illinois, Indiana, Minnesota
2025-11-29
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
California, Colorado, Florida, Georgia, Illinois, Indiana, Mississippi, New York
2025-11-28
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone acetate·Docetaxel
Amgen
Phase 3
750
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2025-11-28
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
NCT06994845Primary Immunoglobulin A Nephropathy (IgAN)
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
31
California, Colorado, Florida, Pennsylvania, Utah
2025-11-27
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
NCT07278336Ovarian Cancer
DrugsBevacizumab·Carboplatin
AbbVie
Phase 1
285
California, Colorado, Illinois, Nebraska, Texas, Utah, Virginia
2025-11-27
Recruiting
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
NCT07129252SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Crinetics Pharmaceuticals Inc.
Phase 1/2
150
Arizona, California, Colorado, Connecticut, Georgia, Kentucky, Louisiana, Michigan
2025-11-26
Active, closed
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
NCT07266558SARS-CoV-2
DrugsMRNA-1283·Efluelda (TIV-HD) and Spikevax
ModernaTX, Inc.
Phase 4
30,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-11-26
By invitation
Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome
NCT07450664Prader-Willi Syndrome
Soleno Therapeutics, Inc.
Observational
200
Arizona, California, Colorado, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-11-26
Recruiting
A Prospective, Randomized, Single-blind, Controlled, Multi-center Study to Assess the Safety and Performance of MagnetOsTM Compared to Autogenous Bone Graft in Patients Undergoing Hindfoot or Ankle Fusions.
NCT07225751Ankle Arthrodesis or Arthroplasty, Hindfoot Fusion, Ankle Deformity, Ankle Disease
Kuros Biosurgery AG
Not applicable
126
California, Colorado, Georgia, North Carolina, Pennsylvania, Tennessee, Virginia
2025-11-25
Recruiting
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
NCT07187531Type 1 Diabetes
SAb Biotherapeutics, Inc.
Phase 2
159
California, Colorado, Florida, Georgia, Indiana, Massachusetts, Missouri, New Mexico
2025-11-25
By invitation
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT07256392Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
1,370
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-11-25
Recruiting
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
NCT07213778Symptomatic Venous Thromboembolism (VTE)
DrugsCenvacibart·Acetylsalicylic acid
Regeneron Pharmaceuticals
Phase 3
2,000
California, Colorado, Florida, Illinois, Indiana, Kansas, Maryland, Massachusetts
2025-11-24
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
DrugPrasinezumab
Hoffmann-La Roche
Phase 3
900
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-11-24
Recruiting
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
NCT07403188Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA)
DrugKYV-101
Kyverna Therapeutics
Observational
70
Colorado
2025-11-24
Recruiting
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
NCT07209462Fragile X Syndrome
DrugMRM-3379
Mirum Pharmaceuticals, Inc.
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-11-22
Recruiting
Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
NCT06971939Macular Telangiectasia Type 2 (MacTel)
Neurotech Pharmaceuticals
Phase 4
234
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-11-21
Recruiting
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
NCT07231419Diabetic Peripheral Neuropathic Pain
DrugSuzetrigine
Vertex Pharmaceuticals Incorporated
Phase 3
734
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2025-11-21
Active, closed
Efficacy and Safety of NVX-CoV2705
NCT07086222COVID-19, Sars-CoV-2 Infection
Novavax
Phase 4
6,500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-11-20
Recruiting
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
NCT07136181Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic, Uveal Melanoma, Recurrent, Eye Cancer, Intraocular Melanoma
Novelwise Pharmaceutical Corporation
Phase 1/2
36
Arizona, Colorado, Tennessee
2025-11-20
Recruiting
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
111
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2025-11-19
Recruiting
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
NCT06948448Colorectal Cancer
DrugsONO-4578·Leucovorin·Opdivo·Adrucil
Ono Pharmaceutical Co., Ltd.
Phase 2
144
Arizona, California, Colorado, Florida, Minnesota, Ohio, Pennsylvania, Texas
2025-11-18
Recruiting
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
NCT07186842Advanced Solid Cancers
BioNTech SE
Phase 1/2
245
Colorado, Florida, New York
2025-11-18
Recruiting
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
NCT07192432HER2 Expressing Solid Tumors
Vironexis Biotherapeutics Inc.
Phase 1/2
27
California, Colorado, Florida, Minnesota, New Jersey, New York, Ohio, Pennsylvania
2025-11-18
Recruiting
Endovascular Repair With Fenestrated TREO Stent-Graft System in AAA
NCT07026877Abdominal Aortic Aneurysms (AAA)
Bolton Medical
Not applicable
20
Colorado, Florida, Massachusetts, Missouri, New York, Texas, Washington
2025-11-18
Recruiting
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
NCT07290803Atopic Dermatitis
Sanofi
Observational
1,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Michigan
2025-11-17
Recruiting
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
NCT07284667Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
ACADIA Pharmaceuticals Inc.
Phase 2
153
Alabama, California, Colorado, Florida, Massachusetts, Mississippi, Missouri, Nebraska
2025-11-14
Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
NCT07085104Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
DrugsFludarabine·Cyclophosphamide
Allogene Therapeutics
Phase 1
66
Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas, Kentucky
2025-11-13
Active, closed
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT07074886Multiple Sclerosis
Hoffmann-La Roche
Phase 2
193
California, Colorado, Florida, Maryland, Massachusetts, New York, Tennessee, Washington
2025-11-13
Active, closed
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
NCT07216482Hyperlipidemia
DrugsEnlicitide·Rosuvastatin
Merck Sharp & Dohme LLC
Phase 3
996
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas
2025-11-11
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
1,275
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Hawaii
2025-11-11
Recruiting
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
NCT07112378Eosinophilic Esophagitis (EoE)
DrugDupilumab
Regeneron Pharmaceuticals
Phase 3
20
Arizona, California, Colorado, Georgia, Massachusetts, New York, North Carolina, Pennsylvania
2025-11-10
By invitation
A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
NCT07156578Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc.
Phase 2
25
Colorado, Iowa, Massachusetts, New York, North Carolina, Tennessee
2025-11-10
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101Ulcerative Colitis
DrugsZotemtegrast·Mirikizumab
Eli Lilly and Company
Phase 2
252
Arizona, California, Colorado, Florida, Illinois, Indiana, Kentucky, Massachusetts
2025-11-10
Recruiting
Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain
NCT07226258Osteoarthritis Knee Pain
Saol Therapeutics Inc
Phase 3
150
California, Colorado, District of Columbia, Florida, Minnesota, North Carolina, Oklahoma, Oregon
2025-11-07
Recruiting
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT07227168Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer
DrugPembrolizumab
Sutro Biopharma, Inc.
Phase 1
200
California, Colorado, District of Columbia, Florida, Massachusetts, New York, Texas, Virginia
2025-11-07
Recruiting
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
NCT07220876Open Angle Glaucoma (OAG)
Avisi Technologies Inc.
Not applicable
165
Arizona, California, Colorado, Ohio, Pennsylvania, Texas, Wisconsin
2025-11-07
Recruiting
Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control
NCT07190807Chronic Pain, Intractable Pain, Low Back Pain, Chronic Low-back Pain
Boston Scientific Corporation
Not applicable
70
Colorado, Florida, Louisiana, New York, Pennsylvania, South Carolina, Texas
2025-11-07
Recruiting
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
NCT07015242Lymphoma
DrugsProcarbazine·Breyanzi·Calcium folinate·Temozolomide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
65
Colorado, Florida, Illinois, Massachusetts, Missouri, New Jersey, New York, Ohio
2025-11-06
Recruiting
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization
DrugAZD0292
AstraZeneca
Phase 2
435
California, Colorado, District of Columbia, Florida, Georgia, Kansas, Michigan, Minnesota
2025-11-06
Recruiting
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT07007065Neovascular Age-related Macular Degeneration
DrugSurabgene Lomparvovec
AbbVie
Phase 3
561
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa
2025-11-05
Active, closed
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
NCT07220642Obesity, Overweight
DrugCagrilintide
Novo Nordisk A/S
Phase 3
300
California, Colorado, Florida, Illinois, Indiana, Missouri, North Carolina, Virginia
2025-11-05
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080Non-Small Cell Lung Cancer
DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
500
California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, Nevada
2025-11-05
Recruiting
Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA
NCT07089576Aortic Arch Aneurysm, Aortic Arch Dissection, Chronic Aortic Dissection, Acute Aortic Dissection
Artivion Inc.
Not applicable
132
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Maryland
2025-11-04
Active, closed
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
NCT07215520COVID-19
DrugCOVID-19 mRNA Vaccine
CastleVax Inc.
Phase 2
200
Colorado, Massachusetts
2025-11-03
Recruiting
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
NCT07049575Hidradenitis Suppurativa
DrugRuxolitinib
Incyte Corporation
Phase 1
24
Arizona, California, Colorado, Florida, Georgia, Indiana, Kentucky, Louisiana
2025-11-03
Active, closed
At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]
NCT07163221Rheumatoid Arthritis (RA)
DrugConventional Synthetic DMARD
SecondWave Systems Inc.
Not applicable
60
Arizona, California, Colorado, Minnesota
2025-11-03
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Ribociclib·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-11-03
Recruiting
A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
NCT06699121Primary Sclerosing Cholangitis (PSC)
LISCure Biosciences
Phase 2
87
California, Colorado, Iowa, Maryland, Minnesota, Tennessee, Washington
2025-11
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,205
Alabama, Arizona, California, Colorado, Florida, Indiana, Maryland, Michigan
2025-10-31
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037Non-small Cell Lung Cancer (NSCLC)
DrugsDato-DXd·Docetaxel
AstraZeneca
Phase 3
400
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Illinois
2025-10-31
Recruiting
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051Bronchiectasis
DrugGSK3862995B
GlaxoSmithKline
Phase 2
363
Alabama, Arizona, California, Colorado, Florida, Indiana, Louisiana, Maryland
2025-10-30
Recruiting
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
NCT07332000Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
DrugsAglatimagene besadenovec·Valacyclovir
Candel Therapeutics, Inc.
Phase 2
45
Arizona, Colorado, Maryland, Nevada, New Jersey, South Carolina
2025-10-30
Active, closed
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
NCT06851559Eosinophilic Esophagitis
DrugVonoprazan
Phathom Pharmaceuticals, Inc.
Phase 2
95
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois
2025-10-30
Recruiting
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
NCT07219615Chronic Spontaneous Urticaria
DrugsLitfulo·Ritlecitinib
Pfizer
Phase 2
200
Arizona, Arkansas, California, Colorado, Illinois, Maryland, Michigan, Oklahoma
2025-10-30
Recruiting
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
NCT07182149HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Normunity AccelCo, Inc.
Phase 1
150
Colorado, Connecticut, District of Columbia, Massachusetts, Minnesota, Missouri, New Jersey, Ohio
2025-10-30
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
NCT06701656Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
DrugBevacizumab
PPD Development, LP
Phase 2
200
Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts
2025-10-28
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
DrugAvacincaptad Pegol
ONL Therapeutics
Phase 2
324
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2025-10-28
Recruiting
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
NCT07221227Non-alcoholic Fatty Liver Disease
DrugEfimosfermin alfa
GlaxoSmithKline
Phase 3
1,200
Arizona, Arkansas, California, Colorado, Florida, Georgia, Kansas, Louisiana
2025-10-24
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin
Hoffmann-La Roche
Phase 3
600
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-24
Recruiting
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
NCT07220564Haemophilia A
Novo Nordisk A/S
Phase 1
30
Colorado, Indiana, Iowa, Pennsylvania
2025-10-23
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173Asthma
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Arizona, California, Colorado, Florida, Illinois, Kentucky, Massachusetts, Nevada
2025-10-22
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
DrugsSofe-M·MIRV·Pegylated liposomal doxorubicin·Topotecan
Eli Lilly and Company
Phase 3
1,630
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-10-22
Recruiting
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
NCT07220811Ig-E Mediated Food Allergy
DrugOzureprubart
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Phase 2
100
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Massachusetts
2025-10-22
Recruiting
A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System
NCT07227532Atrial Fibrillation
Biosense Webster, Inc.
Not applicable
276
Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas, Michigan
2025-10-21
Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
NCT07213609Neoplasms, Colorectal, Neoplasms
GlaxoSmithKline
Phase 1/2
47
Colorado, Michigan, Ohio, Tennessee
2025-10-20
Recruiting
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339Pulmonary Disease, Chronic Obstructive
DrugDepemokimab
GlaxoSmithKline
Phase 3
1,196
California, Colorado, Florida, Georgia, Idaho, Kentucky, Louisiana, Maine
2025-10-20
Recruiting
ARC-IM System to Manage Symptomatic Blood Pressure Instability Secondary to Chronic Spinal Cord Injury
NCT07147296Spinal Cord Injuries, Blood Pressure Disorders
ONWARD Medical, Inc.
Not applicable
60
Arkansas, Colorado, Florida, Georgia, Kentucky, Maryland, Massachusetts, Minnesota
2025-10-17
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Maryland
2025-10-15
Recruiting
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
NCT07206056Progressive Metastatic Castrate Resistant Prostate Cancer
DrugLuxdegalutamide
Novartis Pharmaceuticals
Phase 1/2
188
Colorado, Florida, Georgia, Kansas, Massachusetts, North Carolina, Ohio, Washington
2025-10-15
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
4,500
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-10-15
Recruiting
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
NCT07221500Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
DrugBexobrutideg
Nurix Therapeutics, Inc.
Phase 2
100
Arizona, California, Colorado, Florida, Indiana, Iowa, Maryland, Michigan
2025-10-15
Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
NCT07174583Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3
DrugsDurvalumab·Carboplatin
IDEAYA Biosciences
Phase 1/2
262
Colorado, Florida, Indiana, Michigan, New York, Pennsylvania, Tennessee, Texas
2025-10-14
By invitation
Novel On-body Evaluation of Cardiac Health for Oncology
NCT07158450Cardiotoxicity, Heart Failure
Skribe Medical
Observational
1,000
Colorado, Florida, Illinois, Louisiana, New York, Pennsylvania, Tennessee, Virginia
2025-10-09
Active, closed
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
NCT07176390Arthritis, Rheumatoid
DrugsTulisokibart·Methotrexate
Merck Sharp & Dohme LLC
Phase 2
185
Arizona, California, Colorado, Florida, Illinois, Michigan, Missouri, Nebraska
2025-10-08
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07184996Ulcerative Colitis
DrugDuvakitug
Sanofi
Phase 3
980
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-08
Recruiting
A Study of CTD402 in T-ALL/LBL Patients
NCT07070219Acute Lymphocytic Leukemia Refractory, Lymphoma, Lymphoblastic
Imviva Bio
Phase 1/2
118
California, Colorado, Illinois, Minnesota, New York, Tennessee, Texas
2025-10-07
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 2/3
1,092
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-03
Recruiting
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
NCT07193511Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Urothelial Cancer
Avenzo Therapeutics, Inc.
Phase 1/2
355
California, Colorado, Connecticut, Florida, Massachusetts, New York, North Carolina, Ohio
2025-10-02
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
DrugDuvakitug
Sanofi
Phase 3
980
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-01
Recruiting
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
NCT07008118Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
120
Arizona, California, Colorado, Florida, Illinois, Maryland, New York, North Carolina
2025-10-01
By invitation
A Long-Term Study of Navenibart in Participants With Hereditary Angioedema
NCT07204938Hereditary Angioedema (HAE)
DrugNavenibart
Astria Therapeutics, Inc.
Phase 3
145
Arizona, Arkansas, California, Colorado, Maryland, Ohio, Pennsylvania
2025-10-01
Recruiting
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
NCT07175038Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
AllRock Bio, Inc.
Phase 2
40
Arizona, California, Colorado, District of Columbia, Florida, Kansas, Michigan, Ohio
2025-10-01
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
882
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-01
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762Urothelial Cancer
DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
470
Arizona, California, Colorado, District of Columbia, Florida, Kentucky, Maryland, Massachusetts
2025-09-30
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Michigan, Pennsylvania
2025-09-30
Recruiting
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275Primary Membranous Nephropathy
DrugsPovetacicept·Tacrolimus
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-09-30
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336Ulcerative Colitis
Genentech, Inc.
Phase 2
224
California, Colorado, Florida, Illinois, New York, North Carolina, Utah
2025-09-29
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
DrugsPF-08046054·Docetaxel
Pfizer
Phase 3
680
Alabama, Alaska, Arkansas, California, Colorado, Delaware, Florida, Georgia
2025-09-29
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsMevrometostat·Xtandi·Enzalutamide
Pfizer
Phase 3
1,000
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-09-28
Recruiting
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312Acute Myeloid Leukemia (AML)
DrugsZiftomenib·Venclyxto·Ara-C·Daunorubicin
Kura Oncology, Inc.
Phase 3
1,300
Arizona, California, Colorado, Connecticut, Florida, Iowa, Kentucky, Massachusetts
2025-09-26
Recruiting
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
NCT07129993Urothelial Cancer, Bladder Cancer
DrugsDato-DXd·Gemcitabine·Cisplatin·Carboplatin
Daiichi Sankyo
Phase 2/3
630
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-09-26
Active, closed
Real-World Effectiveness of Amniotic Membrane Allografts Versus Standard Wound Care in DFU, VLU, and PU
NCT07223281Diabetic Foot Ulcer (DFU), Venous Leg Ulcers (VLUs), Pressure Ulcers, Bedsores, Decubitus Ulcer
Legacy Medical Consultants
Observational
2,400
Colorado, Michigan, Oklahoma, West Virginia
2025-09-25
Active, closed
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
NCT07159763Influenza
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
10,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-09-25
Recruiting
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
NCT07102381HER2-positive Breast Cancer, Breast Cancer
DrugsZanidatamab·Pertuzumab·Trastuzumab·Docetaxel
Jazz Pharmaceuticals
Phase 2
125
California, Colorado, Florida, Iowa, Louisiana, Maine, Maryland, Michigan
2025-09-24
Recruiting
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
NCT06760546Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia
DrugSetmelanotide
Rhythm Pharmaceuticals, Inc.
Phase 3
39
Alabama, Colorado, Illinois, Massachusetts, Minnesota, New York, Pennsylvania, Washington
2025-09-23
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967Plaque Psoriasis
DrugsUstekinumab·Deucravacitinib
Bristol-Myers Squibb
Phase 3
3,040
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-09-22
Recruiting
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
NCT07140016Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
DrugGilteritinib
Astellas Pharma Global Development, Inc.
Phase 1
40
California, Colorado, Georgia, Illinois, Michigan, Missouri, New Jersey, Texas
2025-09-22
Recruiting
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
DrugZilebesiran
Alnylam Pharmaceuticals
Phase 3
11,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-09-22
Recruiting
Study of Student Flourishing
NCT07259746Healthy
Flourish Science, Inc.
Not applicable
2,500
California, Colorado, Hawaii, Kansas, Rhode Island, Washington, Wisconsin
2025-09-22
Active, closed
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
NCT07221578Social Anxiety Disorder (SAD)
Vanda Pharmaceuticals
Phase 3
500
Arizona, California, Colorado, Florida, Georgia, Louisiana, Maryland, Missouri
2025-09-22
Recruiting
DESTINY-PANTUMOUR04
NCT07124000Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Observational
100
Alabama, Arizona, California, Colorado, Florida, Illinois, Kansas, New Mexico
2025-09-18
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
NCT07190222Chronic Obstructive Pulmonary Disease
DrugLunsekimig
Sanofi
Phase 3
942
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-09-17
Recruiting
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
NCT07207707Solid Tumor Malignancies
Kumquat Biosciences Inc.
Phase 1
78
California, Colorado, Florida, Michigan, Ohio, Texas, Utah, Virginia
2025-09-16
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
DrugEmpasiprubart
argenx
Phase 3
160
Alabama, California, Colorado, District of Columbia, Florida, Louisiana, Pennsylvania, Tennessee
2025-09-16
Recruiting
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
NCT07047144Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3
DrugsApitegromab·Nusinersen·Risdiplam
Scholar Rock, Inc.
Phase 2
52
Arizona, California, Colorado, Georgia, Iowa, Michigan, Pennsylvania, Texas
2025-09-15
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471Osteoarthritis
DrugOrforglipron
Eli Lilly and Company
Phase 3
800
Arizona, California, Colorado, Connecticut, Georgia, Illinois, Kansas, Massachusetts
2025-09-15
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
413
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-09-13
Recruiting
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
NCT07205887Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
DrugsRestoret·Aflibercept
EyeBiotech Ltd.
Phase 2
160
Arizona, California, Colorado, Florida, Illinois, Maryland, Mississippi, New Jersey
2025-09-12
Recruiting
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
NCT07020819Guillain-Barre Syndrome
Annexon, Inc.
Phase 3
30
Arizona, California, Colorado, Florida, Kansas, Louisiana, Massachusetts, Michigan
2025-09-12
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
600
Arkansas, California, Colorado, Delaware, Florida, Georgia, Illinois, Louisiana
2025-09-11
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965Non-Muscle Invasive Bladder Neoplasms
DrugsErdafitinib·Mitomycin C·Gemcitabine
Janssen Research & Development, LLC
Phase 3
220
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana
2025-09-10
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-09-08
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
DrugsJNJ-87189401·Pasritamig
Janssen Research & Development, LLC
Phase 3
1,203
California, Colorado, Connecticut, District of Columbia, Florida, Iowa, Louisiana, Maryland
2025-09-02
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-09-02
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Arizona, Arkansas, California, Colorado, Florida, Maryland, Michigan, Missouri
2025-08-28
Recruiting
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07043400Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugsLeucovorin·Adrucil·Tislelizumab·Capecitabine
BeOne Medicines
Phase 3
351
Arizona, California, Colorado, Florida, Illinois, Kansas, Maine, Missouri
2025-08-27
Active, closed
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
NCT07122193Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors
DrugXeomin
Merz North America, Inc.
Phase 3
300
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-08-27
Recruiting
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
NCT07030257Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC)
Tasca Therapeutics
Phase 1/2
150
Colorado, Florida, Michigan, Missouri, Nebraska, North Carolina, Ohio, Pennsylvania
2025-08-27
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer
DrugsCapivasertib·Fulvestrant
Relay Therapeutics, Inc.
Phase 3
540
Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia
2025-08-26
Recruiting
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
NCT07096843Primary Membranous Nephropathy
DrugBudoprutug
Climb Bio, Inc.
Phase 2
45
Colorado, Florida, Georgia, Indiana, Massachusetts, New York, Texas
2025-08-25
Recruiting
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
NCT07160244Healthy
DrugPrevnar 20
Pfizer
Phase 3
6,000
Alabama, Arizona, California, Colorado, Florida, Idaho, Louisiana, Maryland
2025-08-25
Recruiting
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
NCT07136012Cardiovascular Disease
DrugOlpasiran
Amgen
Phase 3
11,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-08-22
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Alabama, California, Colorado, District of Columbia, Florida, Kentucky, Louisiana, Maryland
2025-08-22
Recruiting
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
NCT06959524Coronary Arterial Disease (CAD), de Novo Lesions in Native Coronary Arteries
Boston Scientific Corporation
Not applicable
1,616
Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-08-21
Active, closed
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
NCT06961344Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Tisento Therapeutics
Phase 2
44
California, Colorado, Georgia, Massachusetts, New York, Ohio, Pennsylvania, Texas
2025-08-18
Active, closed
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
DrugsTarlatamab·Etoposide·Durvalumab·Carboplatin
Amgen
Phase 3
350
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-08-18
Recruiting
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
NCT06887192Psychosis Associated With Alzheimer's Disease
DrugML-007C-MA
MapLight Therapeutics
Phase 2
300
Arizona, California, Colorado, Florida, Georgia, Louisiana, Nevada, New Jersey
2025-08-15
Recruiting
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318Immune Thrombocytopenic Purpura (ITP)
DrugMezagitamab
Takeda
Phase 3
150
Arkansas, California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky
2025-08-14
Recruiting
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
NCT07019922Epileptic Encephalopathy, SCN2A Encephalopathy
Praxis Precision Medicines
Phase 3
40
California, Colorado, Illinois, Ohio, Pennsylvania, Tennessee
2025-08-13
Recruiting
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
NCT06988618Prurigo Nodularis
Galderma R&D
Observational
600
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2025-08-11
Recruiting
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
NCT06908928Triple Negative Breast Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1
52
California, Colorado, Illinois, Massachusetts, New York
2025-08-11
Active, closed
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT07076199Diabetes Mellitus, Type 1
DrugsInsulin aspart·Insulin glargine·Insulin icodec
Novo Nordisk A/S
Phase 3
877
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-08-11
Recruiting
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06896916Multiple Myeloma
DrugsEtentamig·Iberdomide
AbbVie
Phase 1
135
California, Colorado, Missouri, New Jersey, New York, North Carolina, Washington
2025-08-07
Recruiting
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
NCT06624644Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma, Unresectable Melanoma
DrugsTemozolomide·Pembrolizumab
Linnaeus Therapeutics, Inc.
Phase 2/3
135
California, Colorado, Florida, Massachusetts, New Mexico, Pennsylvania
2025-08-06
Active, closed
Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage
NCT06655207Post Partum Haemorrhage, Maternal Care Patterns, High Risk Pregnancy
Baymatob Operations Pty Ltd
Not applicable
1,000
Colorado, Louisiana, New York, Ohio, Pennsylvania
2025-08-06
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
DrugsPrednisolone/prednisone·Saruparib·Abiraterone
AstraZeneca
Phase 3
700
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Maryland
2025-08-06
Recruiting
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
NCT07029581Lewy Body Dementia Psychosis
DrugACP-204
ACADIA Pharmaceuticals Inc.
Phase 2
180
California, Colorado, District of Columbia, Florida, Hawaii, Illinois, Kansas, New York
2025-08-06
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
DrugsTzield·Teplizumab
Sanofi
Phase 3
723
Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho, Kentucky
2025-08-06
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965Breast Cancer
DrugsPrifetrastat·Exemestane·Everolimus·Fulvestrant
Pfizer
Phase 3
400
Arizona, California, Colorado, Connecticut, District of Columbia, Georgia, Illinois, Maryland
2025-08-05
Recruiting
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
NCT07133308Alopecia Areata
DrugDeuruxolitinib
Sun Pharmaceutical Industries, Inc.
Phase 3
355
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2025-08-05
Recruiting
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
NCT07089888Tophaceous Gout
DrugsDotinurad·Allopurinol
Crystalys Therapeutics
Phase 3
250
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-08-04
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07005102Non-Squamous Non-Small Cell Lung Cancer, c-MET
DrugsTelisotuzumab Adizutecan·Osimertinib·Pemetrexed·Cisplatin
AbbVie
Phase 2/3
854
Arizona, California, Colorado, Florida, Hawaii, Iowa, Nebraska, Nevada
2025-08-03
Recruiting
A Study of Dotinurad Versus Allopurinol in Participants With Gout
NCT07089875Gout
DrugsDotinurad·Allopurinol
Crystalys Therapeutics
Phase 3
500
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-08-01
Recruiting
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
DrugsPalbociclib·Fulvestrant
Bristol-Myers Squibb
Phase 1
234
Alabama, California, Colorado, Massachusetts, Missouri, New Hampshire, New York, Texas
2025-08-01
Recruiting
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
NCT06398418Solid Tumor, Adult, Solid Tumor, Melanoma, Basal Cell Cancer
Rise Therapeutics LLC
Phase 1
33
Colorado, Tennessee
2025-08-01
Active, closed
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711Severe Alopecia Areata
DrugsRitlecitinib higher·Ritlecitinib lower
Pfizer
Phase 3
208
California, Colorado, District of Columbia, Florida, Illinois, Indiana, Maryland, Michigan
2025-07-31
Recruiting
Inspire UAS High Apnea Hypopnea Index (AHI)/High Body Mass Index (BMI) Post-Approval Study
NCT07113288Obstructive Sleep Apnea (OSA)
Inspire Medical Systems, Inc.
Observational
70
Colorado, Florida, Illinois, Kansas, New York
2025-07-31
Recruiting
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
NCT07073547Multiple Myeloma
DrugAZD0120
AstraZeneca
Phase 1
40
Arizona, California, Colorado, Florida, Georgia, Iowa, Minnesota, Missouri
2025-07-31
Active, closed
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
NCT07021066Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer
DrugBL-M05D1
SystImmune Inc.
Phase 1
160
Arizona, California, Colorado, Connecticut, Louisiana, Michigan, New Jersey, Tennessee
2025-07-30
Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
NCT06990399Macular Edema Secondary to Inflammation
DrugKSI-101
Kodiak Sciences Inc
Phase 3
600
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2025-07-30
Recruiting
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
NCT07002034Adjustment Disorder
DrugRE104
Reunion Neuroscience Inc
Phase 2
100
Alabama, Arizona, California, Colorado, Florida, Georgia, Hawaii, Illinois
2025-07-30
Recruiting
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
NCT07024784Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
DrugsIMGN151·Olaparib·Bevacizumab·Carboplatin
AbbVie
Phase 2
377
California, Colorado, Minnesota, New Jersey, New York, Ohio, Oklahoma, Oregon
2025-07-30
Recruiting
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
NCT06850805Chronic Rhinosinusitis Without Nasal Polyps
Optinose US Inc.
Phase 3
84
Alabama, Arizona, California, Colorado, Georgia, Illinois, Kentucky, Maryland
2025-07-28
Recruiting
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT06858319Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
220
Colorado, Florida, Iowa, New York, Tennessee, Texas
2025-07-28
Recruiting
Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387
NCT07010159Pericarditis, Pericarditis Acute, Recurrent Pericarditis
DrugKPL-387
Kiniksa Pharmaceuticals International, plc
Phase 2/3
325
Arizona, California, Colorado, District of Columbia, Georgia, Illinois, Indiana, Kansas
2025-07-25
Recruiting
A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting
NCT07700966Recessive Dystrophic Epidermolysis Bullosa
Abeona Therapeutics, Inc
Observational
250
California, Colorado, Illinois, Texas
2025-07-25
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
DrugMRG007
ArriVent BioPharma, Inc.
Phase 1
572
California, Colorado, Florida, Tennessee, Texas, Virginia, Washington
2025-07-25
Recruiting
Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®
NCT07070115Hiatal Hernia
Tela Bio Inc
Not applicable
173
Alabama, Colorado, Kentucky, North Carolina, Texas
2025-07-25
Active, closed
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
NCT07146022Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia
DrugVDPHL01
Veradermics, Inc.
Phase 3
552
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2025-07-25
Recruiting
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
NCT06911632Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Tempus AI
Not applicable
900
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Kentucky
2025-07-23
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsSigvotatug vedotin·Pembrolizumab
Pfizer
Phase 3
714
California, Colorado, District of Columbia, Florida, Illinois, Kansas, Maine, Massachusetts
2025-07-23
Recruiting
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT07064759Neovascular Age-Related Macular Degeneration (nAMD)
DrugsEYLEA (aflibercept)·4D-150 IVT
4D Molecular Therapeutics
Phase 3
480
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Maryland
2025-07-22
Recruiting
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
NCT07123038Rheumatoid Arthritis (RA), Hidradenitis Suppurativa (HS)
Sonoma Biotherapeutics, Inc.
Observational
36
California, Colorado, Illinois, Massachusetts, Minnesota, North Carolina, Texas
2025-07-22
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
11,800
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-07-22
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
586
California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan, Mississippi
2025-07-21
Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807Breast Neoplasms
DrugsPatritumab deruxtecan·Pegylated liposomal doxorubicin·Abraxane·Xeloda
Merck Sharp & Dohme LLC
Phase 3
1,000
Alabama, Arizona, California, Colorado, Delaware, Florida, Kentucky, New Jersey
2025-07-21
Recruiting
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273Bipolar Disorder Type I With Mania
DrugsValproate·Lamotrigine·Lithium·KarXT
Bristol-Myers Squibb
Phase 3
450
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-07-18
Recruiting
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
NCT06953089Solid Tumors
DrugsDB-1305/BNT325·Pumitamig
DualityBio Inc.
Phase 2
450
California, Colorado, Florida, Georgia, Maryland, Nebraska, New York, Oregon
2025-07-18
By invitation
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
NCT06605105Major Depressive Disorder
DrugCYB003
Cybin IRL Limited
Phase 3
468
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-07-18
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri
2025-07-17
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Arizona, Colorado, Florida, Louisiana, Massachusetts, Minnesota, New York, Ohio
2025-07-16
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
NCT07011745Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
426
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2025-07-16
Recruiting
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma
DrugsBevacizumab biosimilar·Calderasib·Mvasi·Erbitux
Merck Sharp & Dohme LLC
Phase 3
477
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Iowa
2025-07-16
Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
NCT06996080Macular Edema Secondary to Inflammation
DrugKSI-101
Kodiak Sciences Inc
Phase 3
300
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2025-07-16
Recruiting
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
NCT07013474COVID-19 Infection
DrugsIbuzatrelvir·Veklury·Remdesivir
Pfizer
Phase 3
300
California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois, Maryland
2025-07-14
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
586
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Minnesota
2025-07-14
Recruiting
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
NCT06764940HER2-negative Breast Cancer Patients With Brain Metastases
DrugsUtidelone·Capecitabine
Biostar Pharma, Inc.
Phase 2
120
California, Colorado, Georgia, Illinois, Maryland, Nevada, New York, Texas
2025-07-14
Recruiting
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
NCT06988605Atopic Dermatitis
Galderma R&D
Observational
1,000
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2025-07-14
Active, closed
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
NCT07015983Lupus Erythematosus, Systemic, Lupus Nephritis
DrugsZola-cel·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Arizona, California, Colorado, Florida, Georgia, Indiana, Louisiana, Massachusetts
2025-07-14
Recruiting
Prospective Study to Assess a Diagnostic Aid for Cancer
NCT07046260Cancer
Harbinger Health
Observational
2,450
California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas, Louisiana
2025-07-11
Recruiting
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
NCT06868212Chronic Spontaneous Urticaria (CSU)
DrugsRemibrutinib·Dupilumab
Novartis Pharmaceuticals
Phase 3
400
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2025-07-11
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732Alzheimer Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
426
Arizona, California, Colorado, Florida, Louisiana, Maryland, Massachusetts, Michigan
2025-07-10
Active, closed
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556Metastatic Hormone-sensitive Prostate Cancer
DrugsLuxdegalutamide·Abiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 2
168
California, Colorado, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-07-07
By invitation
Amplification and Tinnitus Masker Performance and Benefit for Adults With Hearing Loss and Tinnitus
NCT07298499Hearing Aid, Tinnitus
Starkey Laboratories, Inc
Not applicable
100
Colorado
2025-07-07
Active, closed
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07047118Prostatic Cancer, Castration-Resistant
DrugsLuxdegalutamide·Lu-PSMA
Novartis Pharmaceuticals
Phase 2
138
California, Colorado, Connecticut, Indiana, Massachusetts, Nebraska, New York, Pennsylvania
2025-07-03
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903Transthyretin Amyloidosis With Cardiomyopathy
DrugNucresiran
Alnylam Pharmaceuticals
Phase 3
1,750
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana
2025-07-02
Recruiting
Study With Phage for CF Subjects With Pseudomonas Lung Infection
NCT06998043Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
BiomX Ltd
Phase 2
63
Alabama, Alaska, Arkansas, California, Colorado, Florida, New Jersey, New York
2025-07-02
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
NCT06855277Prostate Cancer
DrugsAAA817·ARPI
Novartis Pharmaceuticals
Phase 3
940
Alabama, California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas
2025-07-01
Rows per page Showing 1–500 of 2068
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/colorado

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,068 of those studies with a site in Colorado.

How many clinical trials are recruiting in Colorado?

1,022 of the 2,068 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 25 have not yet opened recruitment, 956 are active but closed to new participants, and 65 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Colorado), 2,068 studies
PhaseStudiesRecruitingShare
Phase 381336039.3%
Phase 235316817.1%
Not applicable2138410.3%
Phase 12031269.8%
Phase 1/21961279.5%
Observational181948.8%
Phase 2/374443.6%
Phase 434181.6%
Phase EARLY_PHASE1110%

Most active sponsors

Lead sponsors with the most studies (Colorado)
Lead sponsorStudiesRecruiting
AstraZeneca8744
Janssen Research & Development, LLC7133
Eli Lilly and Company6533
Merck Sharp & Dohme LLC6438
Novartis Pharmaceuticals5625
AbbVie5424
Hoffmann-La Roche5217
Pfizer4629
Bristol-Myers Squibb3520
GlaxoSmithKline2818
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.